Neurobiología y fisiopatología de la demencia

1. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: A systematic review and metaanalysis. Alzheimers Dement 2013;9(1):63–75.e2. doi: 10.1016/j. jalz.2012.11.007.

2. Australian Institute of Health and Welfare (AIHW). Dementia in Australia. AIHW, 2022. Available at www.aihw.gov.au/reports/dementia/dementiain-aus/contents/summary [Accessed 1 February 2023].

3. Australian Bureau of Statistics (ABS). Causes of death. ABS, 2021. Available at www.abs.gov. au/statistics/health/causes-death [Accessed 1 February 2023].

4. Fiest KM, Jetté N, Roberts JI, et al. The prevalence and incidence of dementia: A systematic review and meta-analysis. Can J Neurol Sci 2016;43 Suppl 1:S3–50. doi: 10.1017/cjn.2016.18.

5. Peloso GM, Beiser AS, Satizabal  L, et al. Cardiovascular health, genetic risk, and Risk of dementia in the Framingham Heart Study. Neurology 2020;95(10):e1341–50. doi: 10.1212/ WNL.0000000000010306.

6. Takeda S, Rakugi H, Morishita R. Roles of vascular risk factors in the pathogenesis of dementia. Hypertens Res 2020;43:162–67.

7. Bellou V, Belbasis L, Tzoulaki I, Middleton LT, Ioannidis JPA, Evangelou E. Systematic evaluation of the associations between environmental risk factors and dementia: An umbrella review of systematic reviews and meta-analyses. Alzheimers Dement 2017;13(4):406–18. doi: 10.1016/j.

jalz.2016.07.152.

8. Shi L, Chen SJ, Ma MY, et al. Sleep disturbances increase the risk of dementia: A systematic review and meta-analysis. Sleep Med Rev 2018;40:4–16. doi: 10.1016/j.smrv.2017.06.010.

9. Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL. Alzheimer’s disease. Nat Rev Dis Primers 2015;1(1):15056. doi: 10.1038/ nrdp.2015.56.

10. Hardy JA, Higgins GA. Alzheimer’s disease: The amyloid cascade hypothesis. Science 1992;256(5054):184–85. doi: 10.1126/science.1566067.

11. Lane CA, Hardy J, Schott JM. Alzheimer’s disease. Eur J Neurol 2018;25(1):59–70. doi: 10.1111/

ene.13439.

12. Bateman RJ, Aisen PS, De Strooper B, et al. Autosomal-dominant Alzheimer’s disease: A review and proposal for the prevention of Alzheimer’s disease. Alzheimers Res Ther 2011;3(1):1. doi: 10.1186/alzrt59.

13. Holper S, Watson R, Yassi N. Tau as a biomarker of neurodegeneration. Int J Mol Sci 2022;23(13):23. doi: 10.3390/ijms23137307.

14. Aschenbrenner AJ, Gordon BA, Benzinger TLS, Morris JC, Hassenstab JJ. Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease. Neurology 2018;91(9):e859–66. doi: 10.1212/ WNL.0000000000006075.

15. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82(4):239–59. doi: 10.1007/BF00308809.

16. Robinson JL, Lee EB, Xie SX, et al. Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain 2018;141(7):2181–93. doi: 10.1093/brain/awy146.

17. Jellinger KA. Prevalence and impact of cerebrovascular lesions in Alzheimer and Lewy body diseases. Neurodegener Dis 2010;7(1–3):112–15. doi: 10.1159/000285518.

18. Jellinger KA, Attems J. Incidence of cerebrovascular lesions in Alzheimer’s disease: A postmortem study. Acta Neuropathol 2003;105(1):14–17. doi: 10.1007/s00401-002-0634-5.

19. Xia Y, Yassi N, Raniga P, et al. Comorbidity of cerebrovascular and Alzheimer’s disease in aging. J Alzheimers Dis 2020;78(1):321–34. doi: 10.3233/JAD-200419.

20. Yassi N, Hilal S, Xia Y, et al. Influence of comorbidity of cerebrovascular disease and amyloid-β on Alzheimer’s disease. J Alzheimers Dis 2020;73(3):897–907. doi: 10.3233/JAD-191028.

21. Greenberg SM, Vernooij MW, Cordonnier C, et al. Cerebral microbleeds: A guide to detection and interpretation. Lancet Neurol 2009;8(2):165–74. doi: 10.1016/S1474-4422(09)70013-4.

22. Charidimou A, Boulouis G, Frosch MP, et al. The Boston criteria version 2.0 for cerebral amyloid angiopathy: A multicentre, retrospective, MRIneuropathology diagnostic accuracy study. Lancet Neurol 2022;21(8):714–25. doi: 10.1016/S1474-4422(22)00208-3.

23. Sepehry AA, Lang D, Hsiung GY, Rauscher A. Prevalence of brain microbleeds in Alzheimer disease: A systematic review and meta-analysis on the influence of neuroimaging techniques. AJNR Am J Neuroradiol 2016;37(2):215–22. doi: 10.3174/ajnr.A4525.

24. Calsolaro V, Edison P. Neuroinflammation in Alzheimer’s disease: Current evidence and future directions. Alzheimers Dement 2016;12(6):719–32. doi: 10.1016/j.jalz.2016.02.010.

25. Ferreira-Vieira TH, Guimaraes IM, Silva FR, Ribeiro FM. Alzheimer’s disease: Targeting the cholinergic system. Curr Neuropharmacol 2016;14(1):101–15. doi: 10.2174/1570159X13666150 716165726.

26. Villemagne VL, Burnham S,  ourgeat P, et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: A prospective cohort study. Lancet Neurol 2013;12(4):357–67. doi: 10.1016/S1474-4422(13)70044-9.

27. Jack CR Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer’s disease: An updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013;12(2):207–16. doi: 10.1016/S1474-4422(12)70291-0.

28. Karikari TK, Pascoal TA, Ashton  J, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer’s disease: A diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol 2020;19(5):422–33. doi: 10.1016/S1474-4422(20)30071-5.

29. Thijssen EH, La Joie R, Wolf A, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration. Nat Med 2020;26(3):387–97.doi: 10.1038/s41591-020-0762-2.

30. Karikari TK, Benedet AL, Ashton NJ, et al. Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative. Mol Psychiatry 2021;26(2):429–42. doi: 10.1038/s41380-020-00923-z.

31. McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology 2017;89(1):88–100. doi: 10.1212/WNL.0000000000004058.